SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network is trending as the community discusses potential catalysts including upcoming news, partnerships, and the possibility of a major exchange listing. Bullish sentiment is fueled by comparisons to early XRP and anticipation of the Zebec Super App launch. Many believe ZBCN is positioned for significant growth and real-world adoption within the evolving financial landscape.

Archer Aviation, Inc. engages in the development of electric vertical take-off and landing (eVTOL) aircraft. The company was founded by Brett Adcock and Adam Goldstein on October 16, 2018, and is headquartered in San Jose, CA.

Archer Aviation Inc - Ordinary Shares - Class A

Archer Aviation Inc

Archer Aviation is trending amidst discussions around its potential collaboration with Tesla and upcoming airshow demonstrations. Community members are actively debating the company's technology, particularly its flight time and vertical takeoff capabilities, with bullish and bearish investors staking their claims. The stock's high trading volume and short interest are also fueling speculation about a potential short squeeze.

Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It engages in development and commercialization of therapies across several end markets within ophthalmology. The company was founded by Olav B. Bergheim, Morteza Gharib, and Richard Hill on July 14, 1998 and is headquartered in Aliso Viejo, CA.

Glaukos Corporation

Glaukos ($GKOS) is trending due to positive Phase 3 trial results for its iDose TR glaucoma treatment, which met primary efficacy endpoints and showed a favorable safety profile. The community is actively discussing the potential for this innovative drug delivery system to disrupt the glaucoma treatment market. Analysts are updating ratings and price targets, reflecting optimism about Glaukos's pipeline and market position in ophthalmic therapies.

Roundhill ETF Trust - Roundhill WeeklyPay Universe ETF

Roundhill WeeklyPay™ Universe ETF

The Roundhill WeeklyPay™ Universe ETF ($WPAY) is trending as investors discuss its weekly dividend payouts and compare it to other high-yield ETFs. Community members are actively sharing dividend amounts and payout schedules, while also debating its valuation and potential for NAV erosion. Some are rotating into $WPAY from other dividend plays, drawn to its promise of consistent income.

OneMain Holdings, Inc. is a consumer finance company, which engages in the origination, underwriting, and servicing of personal loans, primarily to non-prime customers. It operates through the Consumer and Insurance segment. The Consumer and Insurance segment offers services to secured and unsecured personal loans, voluntary credit, and non-credit insurance, and related products through its combined branch network, digital platform, and centralized operations. The company was founded on August 5, 2013, and is headquartered in Evansville, IN.

OneMain Holdings Inc

OneMain Holdings ($OMF) is trending amid discussions around financial sector strength and unusual options activity indicating bearish sentiment. Despite concerns about the political environment and macroeconomics, community members highlight the stock's value, dividend yield, and upcoming earnings as potential catalysts. Recent reports show varying analyst ratings and price target adjustments, reflecting uncertainty in the current market.

Tenable Holdings, Inc. engages in the development of security software solutions. It offers Cyber Exposure which is a discipline for managing and measuring cybersecurity risk in the digital era. Its products include tenable.io, tenable.sc, tenable.ot, and nessus professional. The firm delivers solutions in the field of application security, cloud security, compliance, energy, finance, healthcare, and retail. The company was founded by John C. Huffard, Jr. and Renaud M. Deraison in 2002 and is headquartered in Columbia, MD.

Tenable Holdings Inc

Tenable Holdings is trending amid discussions of its potential as an AI protection acquisition target and overall cybersecurity sector dynamics. Community members are weighing the company's merits against competitors, with some expressing disappointment in its muted market response despite positive earnings, while others suggest it's a hidden gem. Additionally, recent analyst rating adjustments and price target updates are contributing to the ongoing conversation.

Roundhill ETF Trust - Roundhill PLTR WeeklyPay ETF

PLTW is trending due to discussions surrounding its weekly distribution payouts and overall performance. Community members are comparing it to similar income-generating ETFs, highlighting both its price appreciation and consistent dividend payments. Some are speculating about its long-term potential as a steady income stream, while others discuss strategies for reinvesting dividends.

Investment Managers Series Trust II - Tradr 2X Long UPST Daily ETF

Tradr 2X Long UPST Daily ETF

Traders are actively discussing $UPSX, a 2x leveraged ETF for Upstart, with many highlighting it as a way to amplify potential gains from $UPST, especially amid anticipation of future rate cuts. The community is weighing the risks and rewards of using the ETF, with some expressing concerns about its correlation to the underlying stock and others seeing it as a potential high-reward play. Overall sentiment leans bullish, with some expecting a significant move if $UPST rebounds.

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Novartis AG - ADR

Novartis AG

Novartis ($NVS) is trending due to unusual options activity and all-time high watch status, signaling strong momentum and bullish sentiment. Community discussions revolve around the potential impact of tariffs on the pharmaceutical industry and speculation about new acquisitions to boost their pipeline. Option traders are showing bullish sentiment with high call option flow on the stock.

Morgan Stanley operates as a global financial services company. The firm provides investment banking products and services to its clients and customers including corporations, governments, financial institutions, and individuals. It operates through the following segments: Institutional Securities, Wealth Management, and Investment Management. The Institutional Services segment provides financial advisory, capital-raising services, and related financing services on behalf of institutional investors. The Wealth Management segment offers brokerage and investment advisory services covering various types of investments, including equities, options, futures, foreign currencies, precious metals, fixed-income securities, mutual funds, structured products, alternative investments, unit investment trusts, managed futures, separately managed accounts, and mutual fund asset allocation programs. The Investment Management segment provides equity, fixed income, alternative investments, real estate, and merchant banking strategies. The company was founded by Harold Stanley and Henry S. Morgan in 1924 and is headquartered in New York, NY.

Morgan Stanley

Morgan Stanley ($MS) is trending due to a mix of factors, including unusual options activity and analyst ratings adjustments. Community discussions include call options activity, potential share buybacks, and its performance relative to peers in the financial sector. Some traders are noting technical indicators and potential entry points, while others discuss the broader market context.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Apellis Pharmaceuticals is drawing renewed attention from short sellers even as its stock extends a rebound sparked by better-than-expected&nbsp;bottom-line results.Short interest as a percentage of free float rose to 21.1% last week, the highest in three weeks, after bottoming near 21% in late July, according to Ortex data compiled by The Fly.&nbsp;Days-to-cover climbed to 2.8 from 2.6, although volumes stayed heavy following the earnings release, limiting further upside pressure.Shares gained 13.5% in the five sessions through Thursday and have now rallied 45% since July 31, when Apellis reported a second-quarter loss of $0.33 per share, narrower than&nbsp;analysts’ expectations.&nbsp;<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> rose 0.5% on Friday to close at $27.75, its highest level in six months, extending a four-session winning streak.Revenue of $178.5 million missed consensus by about $10 million, but investors cheered the earnings surprise along with regulatory and business updates.&nbsp;Quarterly sales were driven by $151 million from Syfovre, its treatment for geographic atrophy, and $21 million from Empaveli for paroxysmal nocturnal hemoglobinuria. Apellis also secured FDA approval of Empaveli for rare kidney diseases C3G and primary IC-MPGN, the first approved therapies for these conditions.Additionally, Apellis signed a capped royalty deal with Sobi worth up to $300 million for ex-U.S. Aspaveli sales and ended June with $370 million in cash.&nbsp;The company said the combination of cash, the Sobi payment, and future revenues should be sufficient to fund operations to profitability.Following the quarterly results, Goldman Sachs&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/retail-buzz-surges-for-apellis-as-goldman-hikes-price-target-after-solid-syfovre-sales-fda-win-for-kidney-drug/chr3ZbiRdGS">raised its price target</a> to $26 from $24, citing strong quarterly execution and long-term potential across its complement-focused pipeline.&nbsp;Citi lifted its target to $46 from $41, calling Empaveli “best-in-class,” while Scotiabank raised its target to $22 on confidence in launch execution. Baird, BofA, and Morgan Stanley also issued upward revisions earlier in August, reflecting improving sentiment.Despite the rebound, the pickup in short positioning suggests some investors expect profit-taking after the momentum-driven surge.On Stocktwits, retail sentiment for Apellis&nbsp;remained ‘bearish’ amid ‘extremely low’ message volume.Apellis’ stock has declined 13% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

APLS stock has declined 13% so far in 2025. (Photo credit: Getty Images)

Apellis Short Bets Edge Higher As Stock Jumps 45% Since Late July Q2 Report — Retail Traders Stay Wary

Apellis stock has surged since its earnings, but rising short interest suggests some investors are betting on profit-taking.

Equity

Retail chatter around Apellis Pharmaceuticals spiked Thursday after Goldman Sachs raised its price target to $26 from $24, citing strong quarterly performance and long-term growth potential through its pipeline of immune system therapies.Goldman’s move came on the heels of Apellis’ second-quarter earnings report, which showed total revenue of $178 million.&nbsp;Syfovre, the company’s treatment for geographic atrophy,&nbsp;generated $151 million in U.S. net product sales,&nbsp;representing a 6% quarter-over-quarter&nbsp;increase in injection volume. Despite a $13 million revenue impact due to increased free sample usage linked to co-pay assistance constraints, the product maintained a dominant market position with over 60% share of new GA patient starts.&nbsp;Empaveli contributed $20.8 million in sales, supported by high compliance rates.The FDA’s recent approval of Empaveli for patients aged 12 and older with C3G and IC-MPGN added another major catalyst. Backed by Phase 3 Valiant trial data, the decision cleared the way for Empaveli’s use in two rare kidney diseases that impact approximately 5,000 patients in the U.S.&nbsp;The trial showed a 68% drop in urinary protein levels, steady kidney function, and clearance of C3 deposits, which are key indicators of kidney health. The label also includes patients with post-transplant recurrence of C3G.Analyst sentiment has improved notably in recent weeks. Citi raised its price target to $46 from $41, calling Empaveli “best-in-class” and a potential growth driver. Scotiabank lifted its target to $22, highlighting confidence in the company’s ability to execute on the Empaveli launch. Baird, BofA, and Morgan Stanley also issued upward revisions earlier this month.Apellis also strengthened its balance sheet through a $300 million royalty agreement with Sobi, selling 90% of future ex-U.S. royalties on Aspaveli, the ex-U.S. brand of Empaveli, for $275 million upfront.&nbsp;The deal includes a $25 million milestone tied to potential EMA approval for the new kidney indications later this year.On Stocktwits, retail sentiment was ‘extremely bullish’ late Thursday amid a 72% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> has declined 32.6% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail chatter around Apellis Pharmaceuticals (APLS) spiked Thursday after Goldman Sachs raised its price target to $26 from $24. (Photo credit: Getty Images)

Retail Buzz Surges For Apellis As Goldman Hikes Price Target After Solid Syfovre Sales, FDA Win For Kidney Drug

Goldman Sachs cited Apellis’ 6% quarterly injection growth for Syfovre and potential market upside from Empaveli’s newly approved indications in C3G and IC-MPGN, despite recent revenue headwinds from co-pay assistance constraints.

Apellis Pharmaceuticals (APLS) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for Apellis Pharmaceuticals (APLS) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Repligen (RGEN) Lags Q2 Earnings Estimates

Repligen (RGEN) delivered earnings and revenue surprises of -7.50% and +3.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Retail buzz around Apellis Pharmaceuticals&nbsp;intensified on Monday after the FDA approved Empaveli,&nbsp;clearing the way for its use in treating two rare kidney diseases that often lead to kidney failure.&nbsp;The drug is now approved for patients 12 and older with C3G and IC-MPGN, which are conditions that affect 5,000 people in the U.S.&nbsp;The decision was backed by data from the Phase 3 Valiant trial, where patients on Empaveli saw a 68% drop in protein levels in their urine, a key sign of kidney stress, along with steady kidney function and signs that harmful C3 deposits were being cleared.&nbsp;The label also includes patients with post-transplant recurrence of C3G.The FDA decision comes amid a flurry of Wall Street updates on Apellis. Earlier this month, Baird raised its price target on Apellis to $50 from $47, updating its model ahead of second-quarter earnings and noting competitive developments in the C3G space.Morgan Stanley and BofA also raised their price targets, now at $26 and $24, respectively.&nbsp;BofA maintained a ‘Neutral’ rating and noted that Apellis has not provided sales guidance for Syfovre, its treatment for geographic atrophy. Morgan Stanley maintained an ‘Equal Weight’ rating and cited the royalty purchase agreement with Sobi.Apellis recently struck a $300 million royalty deal with Sobi, selling 90% of its future ex-U.S. royalties from Aspaveli, its treatment for a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH), to strengthen its cash position.Apellis will receive $275 million upfront and may earn another $25 million if Aspaveli is approved for C3G and IC-MPGN in Europe.On Stocktwits, retail sentiment for Apellis was ‘extremely bullish’ amid a 2,350% surge in 24-hour message volume.<a href="https://stocktwits.com/symbol/APLS">Apellis’ stock</a> has declined 43.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Chronic kidney disease, computer illustration and light micrograph. The illustration shows the gross anatomy of kidneys with chronic glomerulonephritis. | Image source: Getty Images

Why Retail Investors Are Turning Sharply Bullish On Apellis Pharmaceuticals 

The FDA approved Apellis’ drug Empaveli for two rare kidney diseases, following strong results from a Phase 3 trial. 

Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sanofi's Gene Therapy for Eye Disease Gets FDA's Fast Track Tag

SNY's SAR446597, a one-time intravitreal gene therapy, secures FDA fast track tag for geographic atrophy due to age-related macular degeneration.

Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli

APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.

Why Is Kodiak Sciences (KOD) Up 10.5% Since Last Earnings Report?

Why Is Apellis Pharmaceuticals (APLS) Up 7.2% Since Last Earnings Report?

Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. Its products include EMPAVELI and SYFOVRE. The company was founded by Candace Rose Depp, Pascal Deschatelets, Cedric Francois, and Alec Machiels on September 25, 2009 and is headquartered in Waltham, MA.

Apellis Pharmaceuticals Inc

Will PepsiCo ($PEP) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

PepsiCo Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$23.80
Prev Close	$23.11
Open	$23.09
Dividend Yield	0.00%
50-Day Moving Average	$24.75
Beta	0.84
Avg. Volume	2.28M
PE Ratio	-13.05

52-Week High	$35.72
52-Week Low	$16.10
Market Capitalization	$3.01B
EPS (Annual)	-$1.60
Price to Book	19.21
Revenue Per Employee	$1.1M
Enterprise Value/EBITDA	N/A

APLS
Apellis Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest APLS News

APLS Apellis Pharmaceuticals Inc